15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English A Study Evaluating GS-9620 in Treatment Naive Subjec ...
查看: 1918|回复: 15
go

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B   [复制链接]

Rank: 5Rank: 5

现金
782 元 
精华
帖子
277 
注册时间
2010-12-7 
最后登录
2017-9-23 
1
发表于 2012-5-26 23:33 |只看该作者 |倒序浏览 |打印

    A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
                         This study is currently recruiting participants.   
                              Verified December 2011 by Gilead Sciences   
            
      First Received on April 30, 2012.            Last Updated on May 2, 2012        History of Changes      
  

Sponsor:

Gilead Sciences

Information provided by (Responsible Party):

Gilead Sciences

ClinicalTrials.gov Identifier:

NCT01590641

    Purpose  

Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules. Subjects will be confined on either days 1-3 or days 1-3 and 8-10. Follow-up visits are also required periodically through day 43, and potential viral load follow-up visits at weeks 3 and 6 months post last dose. Study procedures involve blood draws for pharmacokinetic, pharmacodynamic, virologic, and safety assessments



      

  

        Condition              Intervention              Phase      
                Hepatitis B
                HBV
              
                Drug: Single Ascending Dose (SAD) Cohorts GS-9620
                Drug: Multiple Ascending Dose (MAD) Cohorts
              
                Phase 1
              
  

  
              
Study Type:

Interventional

Study Design:

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment

Official Title:

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection

已有 1 人评分现金 收起 理由
MP4 + 3

总评分: 现金 + 3   查看全部评分

Rank: 6Rank: 6

现金
1904 元 
精华
帖子
1665 
注册时间
2011-11-30 
最后登录
2024-5-14 
2
发表于 2012-5-27 06:44 |只看该作者
效果如何呢

Rank: 5Rank: 5

现金
782 元 
精华
帖子
277 
注册时间
2010-12-7 
最后登录
2017-9-23 
3
发表于 2012-5-27 18:16 |只看该作者
回复 咬牙硬挺 的帖子

你难道就不会 google + gs-9620 一下吗?

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

4
发表于 2012-5-27 18:20 |只看该作者
回复 咬牙硬挺 的帖子

他们正在招募,将在2013年报告.

Rank: 6Rank: 6

现金
1748 元 
精华
帖子
429 
注册时间
2006-5-6 
最后登录
2017-6-28 
5
发表于 2012-5-27 19:05 |只看该作者
回复 StephenW 的帖子

开始二期临床了?
Don't waste precious energy on gossip, energy vampires, issues of the past, negative thoughts or things you cannot control. Instead invest your energy in the positive present moment.
别把宝贵的精力浪费在流言蜚语、白耗精力的事情、过去的问题、消极的想法或你不能控制的事情上,而是把精力放在积极的当下。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

6
发表于 2012-5-27 20:10 |只看该作者
本帖最后由 StephenW 于 2012-5-27 20:11 编辑

回复 scilab 的帖子

说是为第1阶段, 但所有的参与者都是乙型肝炎患者, 不同剂量将被测试.

Rank: 5Rank: 5

现金
789 元 
精华
帖子
272 
注册时间
2002-10-4 
最后登录
2014-10-22 
7
发表于 2012-5-27 21:44 |只看该作者
GS-9620对黑猩猩慢性HBV感染的疗效
作者:龙华 译
来源:EASL 2011网站
日期:2011-04-03

  已知激活TLR7可促进干扰素和免疫刺激因子生成,并激活先天性和获得性免疫。GS-9620是一种高效选择性口服TLR7小分子量激动剂,开发用于慢性HBV及HCV感染的治疗。美国圣安东尼奥市西南生物医学研究基金会的Lanford等报告了一项在慢性HBV感染黑猩猩中,评价GS-9620疗效的研究结果,显示GS-9620单药治疗可诱导治疗性抗病毒免疫应答,病毒载量降低伴随着细胞因子及趋化因子应答以及肝脏淋巴细胞浸润。而且对于高病毒滴度的动物,随访期间也可见病毒载量持续受抑。这些结果证实GS-9620具有用于慢性HBV感染治疗的潜力。

  研究中,3只有慢性HBV感染大猩猩被给予GS-9620口服,1 mg/kg,每周3次,共4周,随后2 mg/kg,每周3次再治疗4周。使用LC/MS/MS法确定GS-9620血清浓度,检测血清HBV DNA、HBsAg、HBeAg、CBC和血生化,并使用流式细胞仪分析淋巴细胞亚群的激活,通过点阵仪(Luminex)、肝脏组织学检查和免疫组化分析以及干扰素刺激基因(ISG)的诱导,确定肝脏和血液中细胞因子和趋化因子的水平。

  结果显示,3只动物接受GS-9620治疗后,病毒载量降低了2.0 log,相应血清HBsAg水平降低了50%~61%,HBeAg降低了58%~93%。病毒载量至少降低1 log的持续时间为64天至121天以上,后者指对治疗前高病毒载量动物的监测结束时。使用1 mg/kg剂量即有显著的药代动力学应答,使用2 mg/kg剂量时药代动力学应答进一步增强,ISG增加超过100倍。治疗增加了活化的血液淋巴细胞和NK细胞数量以及凋亡的肝细胞数量,并使肝脏内淋巴细胞浸润逆转。治疗的耐受性良好,不良反应是可逆的,并符合免疫介导的对嗜肝病毒感染的应答。

Rank: 6Rank: 6

现金
1904 元 
精华
帖子
1665 
注册时间
2011-11-30 
最后登录
2024-5-14 
8
发表于 2012-5-28 23:16 |只看该作者
感谢楼上的帖子,期待一下似乎可以

Rank: 6Rank: 6

现金
3118 元 
精华
帖子
555 
注册时间
2005-11-8 
最后登录
2016-3-9 
9
发表于 2012-5-29 08:01 |只看该作者
充满希望!

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

10
发表于 2012-6-14 07:50 |只看该作者
本帖最后由 StephenW 于 2012-6-14 07:51 编辑

Public release date: 13-Jun-2012


Contact: Mika Ono

[email protected]

858-784-2052
Scripps Research Institute

Scripps research scientists show lack of single protein results in persistent viral infection        

                                           IMAGE:                 Michael B. A. Oldstone, Ph.D., is a Professor in the Scripps Research Institute Department of Immunology and Microbial Science.
        
              Click here for more information.                     


LA JOLLA, CA – June 13, 2012 -- Scientists from The Scripps Research Institute have shown a single protein can make the difference between an infection clearing out of the body or persisting for life. The results also show where the defects occur in the immune system without the protein and offer the possibility that targeting this signaling pathway could be beneficial for treatment of persistent viral infections in humans.  Currently hundreds of millions of people around the world are afflicted with persistent viral infections such as HIV, HCV, and HBV.
        The new study is published in the June 14, 2012 issue of the journal Cell Host & Microbe.
        In the new study, a team led by Scripps Research Professor Michael Oldstone showed what happened when a mouse engineered without the protein TLR7 was infected with lymphocytic choriomeningitis virus (LCMV), a virus employed to study the response of the immune system to microbes. While normal mice infected with a LCMV variant called Cl 13 could clear a persistent infection in 60 to 90 days, TLR7-deficient mice were unable to purge the infection throughout their lives.
        "It is well known that RNA from many viruses, including influenza, HIV, and hepatitis C, induce signaling through TLR7," said Kevin Walsh, a research associate in Oldstone's lab and the first author of the study. "We demonstrated that TLR7 plays a significant role in the generation of immune responses required to clear persistent LCMV infection."
        'Biological Warfare'
        In terms of the constant biological warfare between host and microbes, the body is not so much a temple as it is a medieval city. An infectious agent can invade through the skin or mucosa, essentially scaling the walls. Once it's inside it has to deal with the body's first responders, called Toll-like receptors (TLR). These receptors are a pattern-recognition system to alert the immune system.  TLRs form the first line of defense specifically by recognizing molecules of the invading pathogen.
        Ten TLRs have been identified in humans. One of these, TLR7, is located inside the cell within endosomes and the RNA of viruses are detected after they have entered the cell. "TLR7 is a very important receptor in terms of viruses," noted Oldstone.
        In the current study, the researchers chose to use LCMV to understand the role of TLR7. LCMV is, according to Oldstone, "has been, and continues to be a Rosetta Stone to explain basic concepts in immunology and virology."
        Once it was clear that the absence of TLR7 compromised the immune system's ability to clear LCMV infection, Oldstone, Walsh, and their colleagues explored what was happening downstream of the receptor.
        Interestingly, the research demonstrated that even when immune memory cells, which "learn" to fight an infection and impart long-term immunity, were transferred from TLR7-sufficient mice to TLR7-deficient mice, those deficient mice still couldn't clear the infection.
        "The environment within TLR7-deficient mice suppressed the ability of these memory cells to clear the infection," said Walsh.
        Surprisingly Tired Cells
        The team noticed several unexpected things.  First, in the TLR7-deficient mice, there was a profusion of tired T cells. "You see more T cells in TLR7-deficient mice early after infection, but they don't actually clear the infection," said Walsh. "Even though there were more of them, they were less functional."  Second, immune system B cells were severely hampered; specifically, the differentiation and maturation of B cells to plasma cells, cells responsible for generating antiviral antibody, was aborted.  Thus, both essential arms of the immune system, cellular and humoral, required to clear viral infection were compromised.
        Exhausted T cells produce fewer molecules to attack and destroy infected cells. Exhaustion occurs in TLR7-sufficient environments, too—but in those cases there is a resurrection of the T cells 60 to 90 days following infection with LCMV Cl 13, which allows the body to purge the virus. In the TLR7-deficient environment, this resurrection never happens. The exhausted T cells linger, as does the infection. T cell exhaustion is also found in HIV and hepatitis B and C infection.
        "A number of phenomena that LCMV uses to cause a persistent infection is the same that HIV, hepatitis C and B use," said Oldstone. "That's what makes our observation important.  It means that if you understood what is in the environment with loss of TLR7 signaling and how to correct that, you'd have a better chance of treating those persistent human infections. We know how to treat it in the mouse, and people are working very hard to do the treatments in humans."
        

###

In addition to Oldstone and Walsh, authors of the paper, "Toll-like receptor 7 is required for effective adaptive immune responses that prevent persistent virus infection," were John R. Teijaro, Megan J. Welch, Daniel M. Fremgen, and Karl von Tiehl of Scripps Research; Elina I. Zuniga of the University of California, San Diego; Shawn D. Blackburn and E. John Wherry of the University of Pennsylvania School of Medicine; and Richard A. Flavell of Yale University.
        This research was supported by the US National Institutes of Health.
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-16 17:30 , Processed in 0.015945 second(s), 12 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.